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Short title: Mepolizumab for treating severe eosinophilic asthma: An ERG perspective of a NICE 
STA 
Abstract 
As part of its single technology appraisal (STA) process, the National Institute for Health and Care 
Excellence (NICE) invited the company (GlaxoSmithKline) that manufactures mepolizumab 
(Nucala®) to submit evidence on the clinical and cost-effectiveness of mepolizumab for the treatment 
of severe eosinophilic asthma. The School of Health and Related Research Technology Appraisal Group 
(ScHARR-TAG) at the University of Sheffield was commissioned to act as the independent Evidence 
Review Group (ERG). The ERG produced a review of the evidence for the clinical and cost-
effectiveness of mepolizumab as add-on to standard of care (SoC) compared with SoC and omalizumab, 
EDVHGXSRQWKHFRPSDQ\¶VVXEPLVVLRQWR1,&(. The clinical effectiveness evidence in the FRPSDQ\¶V
submission is based predominantly on three randomised controlled trials (DREAM, MENSA and 
SIRIUS) comparing add-on mepolizumab with placebo plus standard of care (SoC). The relevant 
population was defined in terms of degree of asthma severity (4 or more exacerbations in the previous 
year and/or dependency on maintenance oral corticosteroids (mOCS)) and degree of eosinophilia (a 
EORRGHRVLQRSKLOFRXQWRI0 cells/µl in the previous year) based on post hoc subgroup analyses of 
the pivotal trials. Other subpopulations were considered throughout the appraisal, defined by different 
eosinophil measurements, number of exacerbations and dependency (or lack thereof) on mOCS. 
Statistically significant reductions in clinically significant exacerbations were observed in patients on 
mepolizumab compared with SoC meta-analysed across MENSA and DREAM, in the modified ITT 
population (rate ratio [RR]=0.51, 95% confidence interval [CI] 0.42, 0.62),  as well as in the relevant 
population (RR=0.47, 95% CI 0.36, 0.62). In terms of quality of life, differences on the St. GeorJH¶V 
Respiratory Questionnaire in MENSA for add-on mepolizumab 100mg SC vs. placebo were 7 units and 
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7.5 units in the modified ITT and relevant populations respectively. There were a number of issues in 
the clinical evidence base which warrant caution in its interpretation. The ERG noted that the definition 
of SoC used in the trials differed from clinical practice, where severe patients whose asthma is 
uncontrolled start a treatment with mOCS. The FRPSDQ\¶V HFRQRPLF post-consultation analysis 
incorporating a confidential Patient Access Scheme (PAS) estimated that the incremental cost-
effectiveness ratio (ICER) for add-on mepolizumab compared with SoC was £27,418 per quality 
adjusted life year (QALY) gained in the relevant population if patients stopped mepolizumab after one 
year unless (i) the number of exacerbations decreased at least 50% or (ii) a reduction in corticosteroids 
dose was achieved whilst maintaining asthma control. The ERG applied an age-adjustment to all 
utilities and corrected the post-continuation assessment utilities, which resulted in an ICER for add-on 
mepolizumab compared with SoC of £29,163 per QALY gained. The ERG noted that this ICER was 
not robust for patients who continued treatment due to a corticosteroid dose reduction where 
exacerbations had decreased by less than 50%, because corticosteroids dose reduction was not allowed 
in the main trial in which the evidence was gathered (MENSA). The NICE Appraisal Committee (AC) 
concluded that add-on mepolizumab could be recommended as an option for treating severe refractory 
eosinophilic asthma in adults for the relevant population when the stopping rule suggested by the 
company was applied. The AC also concluded that the comparison between mepolizumab and 
omalizumab was not clinically relevant or methodologically robust. 
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Key points for decision makers 
 
x Add-on mepolizumab resulted in clinically and statistically significant reductions in asthma-
related exacerbation rates and an improvement in health-related quality of life. 
 
x The cost-effectiveness of mepolizumab compared to maintenance oral corticosteroids (mOCS) 
or in patients on mOCS is uncertain due to the difficulties with capturing the disutilities and 
costs associated with long-term mOCS use. 
 
x The appraisal committee concluded that the comparison between omalizumab and 
mepolizumab was not clinically relevant, since the two drugs were associated with different 
pathways and different populations.  
 
x NICE recommended mepolizumab as an option for treating severe refractory eosinophilic 
asthma in adults with a blood eosinophil count of  cells/µl in the previous year as well as 
4 or more exacerbations in the previous year and/or dependency on mOCS, if the company 
provided the drug with the discount agreed in the Patient Access Scheme. At 12 months, 
treatment should be continued only if the number of exacerbations is reduced by at least 50% 
or a clinically significant reduction in mOCS use is achieved while maintaining or improving 
asthma control.  
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1. Introduction 
The National Institute for Health and Care Excellence (NICE) is an independent organisation 
responsible for providing national guidance on promoting good health and preventing and treating ill 
health in priority areas with significant impact. Health technologies must be shown to be clinically 
effective and to represent a cost-effective use of National Health Service (NHS) resources in order for 
NICE to recommend their use within the NHS in England. The NICE Single Technology Appraisal 
(STA) process usually covers new single health technologies within a single indication, soon after the 
UK market authorisation [1]. Within the STA process, the company provides NICE with a written 
submission, alongside a mathematical model that summarises the company¶s estimates of the clinical 
and cost effectiveness of the technology. This submission is reviewed by an external organisation 
independent of NICE, the Evidence Review Group (ERG), which consults with clinical specialists and 
produces a report. After consideration of the company¶s submission, the ERG report and a testimony 
from experts and other stakeholders, the NICE Appraisal Committee (AC) formulates preliminary 
guidance, the Appraisal Consultation Document (ACD), which indicates the initial decision of the AC 
regarding the recommendation (or not) of the technology. Stakeholders are then invited to comment on 
the submitted evidence and the ACD, after which a further ACD may be produced or a Final Appraisal 
Determination (FAD) is issued, which is open to appeal. An ACD is not produced when the technology 
is recommended within its full marketing authorisation, in which case, a FAD is produced directly. 
 
This paper presents a summary of the ERG report [2] for the STA of mepolizumab for treating severe 
eosinophilic asthma and a summary of the subsequent development of the NICE guidance for the use 
of this drug in England. Full details of all relevant appraisal documents (including the appraisal scope, 
ERG report, company and consultee submissions, FAD and comments from consultees) can be found 
on the NICE website.[3] 
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2. The Decision Problem 
2.1 Population (severe eosinophilic asthma) 
Asthma is a broad condition characterised by inflammation of the airways leading to reversible (and in 
some cases, irreversible[4]) airway obstruction. Asthma symptoms include wheezing, chest tightness, 
cough and shortness of breath, and exacerbations (worsening) of symptoms can lead to hospitalisations 
and death. It is estimated that approximately 5.4 million people in England and Wales currently receive 
treatment for asthma.[3] Asthma varies in its severity, but in most cases can be controlled with a 
combination of medications, which in the UK are administered in a step-wise manner (steps 1 to 5, with 
1 being the lowest step) until control is reached, according to the British Thoracic Society 
(BTS)/Scottish Intercollegiate Guidelines Network (SIGN) guidelines.[5] The level of treatment 
required is also a measure of the severity of the condition.  
The American Thoracic Society (ATS)/European Respiratory Society (ERS) Task Force defines severe 
asthma as µµDVWKPDWKDWUHTXLUHVWUHDWPHQWZLWKKLJKGRVHLQKDOHGFRUWLFRVWHURLGV,&6SOXVDVHFRQG
FRQWUROOHUDQGRUV\VWHPLFFRUWLFRVWHURLGVWRSUHYHQWLWIURPEHFRPLQJµXQFRQWUROOHG¶RUWKDWUHPDLns 
µXQFRQWUROOHG¶ GHVSLWH WKLV WKHUDS\´[6] These patients suffer from frequent exacerbations, despite 
controller medications, and have a decreased quality of life due to uncontrolled symptoms and treatment 
side effects, as many take oral corticosteroids long-term. The impact of exacerbations on patients varies, 
with some just requiring systemic corticosteroids and others a hospital stay; ultimately, some patients 
die from an asthma exacerbation. There were 1,242 asthma-related deaths in the UK in 2012. Severe 
asthmatics were found to account for 39% of deaths from asthma, [7] and the company 
(GlaxoSmithKline, GSK) argues that as severe asthmatics are only a small proportion of the total asthma 
population (5-10%), mortality is still ³DQLVVXH´ for this population. 
Eosinophilic asthma is a distinct phenotype of asthma characterised by tissue and sputum eosinophilia 
(high levels of a type of white blood cell called eosinophils), a thickening of the basement membrane 
and, often, responsiveness to corticosteroids.[8] It can be present in mild, moderate or severe asthma.[8] 
It is, however, associated with more severe disease, late onset, atopy and steroid refractoriness. The 
diagnosis of eosinophilic asthma is problematic in clinical practice. Induced sputum eosinophil levels 
of 2%[8] are commonly interpreted as indicating eosinophilic disease, however, this test is 
impracticable in routine care. Alternatives include peripheral blood eosinophil counts, fractional 
exhaled nitric oxide (FeNO), serum immunoglobulin E (IgE), and periostin levels. However, a recent 
US review[8] reported that these have limited diagnostic accuracy: levels of blood eosinophils >300 
FHOOVȝ/KDGDSRVLWLYHSUHGLFWLYHYDOXHRIRQO\LQLGHQWLI\LQJDQHRVLQRSKLOLFDVWKPDSKHQRW\SH
(defined as sputum eosinophils of >2%); serum IgE had no correlation with eosinophilia;[9] studies 
relating to FeNO appeared inconsistent;[10-12] and the diagnostic utility of periostin was promising 
but is as yet undetermined.  
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Despite only moderate diagnostic accuracy being reported for blood eosinophils in the literature, the 
test is used in clinical practice to monitor disease.[5] There is no national or international consensus on 
how to interpret such tests; however, clinical advisors to the ERG stated that a OHYHORIFHOOVȝ/LQ
the previous 12 months is a commonly used cut-off.  
2.2 Intervention 
Mepolizumab (Nucala®, GSK) is a humanised anti-interleukin 5 monoclonal antibody (IgG1, kappa). 
Mepolizumab is indicated as an add-on treatment to standard of care (SoC) for severe refractory 
eosinophilic asthma in adult patients.[13] The licensed dose is 100mg administered subcutaneously 
(SC) every 4 weeks with the company assuming that this will be undertaken by a specialist asthma 
nurse. The summary of product characteristics states that the need for continued therapy should be 
FRQVLGHUHGDWOHDVWRQDQDQQXDOEDVLVDVGHWHUPLQHGE\SK\VLFLDQDVVHVVPHQWRIWKHSDWLHQW¶VGLVHDVH
severity and level of control of exacerbations. A confidential Patient Access Scheme (PAS) representing 
a simple discount on list price is in place for mepolizumab.  
2.3 Comparators 
NICE issued a final scope to appraise the clinical and cost effectiveness of mepolizumab, within its 
licensed indication, for the treatment of severe eosinophilic asthma. The main comparator was SoC, 
which, for severe asthma patients, includes the use of high-dose ICS and other controllers, such as long-
DFWLQJȕ-agonists, leukotriene antagonists or theophyllines, and finally daily oral corticosteroids (OCS) 
at the lowest possible dose to achieve adequate control. For people with severe persistent allergic IgE-
mediated eosinophilic asthma, the intervention was also compared with omalizumab (brand name 
Xolair®), a drug recommended by NICE for patients with severe IgE-mediated asthma ZKR ³need 
continuous or IUHTXHQWWUHDWPHQWZLWKRUDOFRUWLFRVWHURLGV´. The marketing authorisation of omalizumab 
states that 16 weeks after the start of treatment, physicians should assess the effectiveness of the 
treatment, and should continue the treatment only in patients whose asthma has markedly improved. A 
confidential PAS is also in place for omalizumab. 
3. The Independent Evidence Review Group Review 
The company provided a submission to NICE on the use of mepolizumab for the treatment of patients 
with severe refractory eosinophilic asthma. In accordance with the process for STAs, the ERG and 
1,&( KDG WKH RSSRUWXQLW\ WR VHHN FODULILFDWLRQ RQ VSHFLILF SRLQWV LQ WKH FRPSDQ\¶V VXEPLVVLRQ LQ
response to which the company provided additional information. The ERG also modified WKHFRPSDQ\¶V
decision analytic model to produce an ERG base case and to assess the impact of alternative parameter 
YDOXHVDQGDVVXPSWLRQVRQWKHPRGHOUHVXOWV7KHHYLGHQFHSUHVHQWHGLQWKHFRPSDQ\¶VVXEPLVVLRQDQG
WKH(5*¶VUHYLHZRIWKDWHYLGHQFHLVVXPmarised here. 
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3.1 Clinical Evidence Provided by the Company 
3.1.1 Pivotal trials 
The clinical effectiveness evidence in the FRPSDQ\¶V VXEPLVVLRQ is based predominantly on three 
randomised controlled trials (RCTs) comparing mepolizumab, as add-on to SoC, with placebo plus SoC 
in patients with severe eosinophilic asthma. Two trials (DREAM[14] and MENSA[15]) had a primary 
endpoint of reduction in exacerbations, whilst one (SIRIUS[16]) enrolled patients receiving 
maintenance oral corticosteroids (mOCS) and had a primary endpoint of reduction in OCS use. In 
addition, data from two open-label extension studies (COSMOS[17] and COLUMBA[18]) enrolling 
patients from the three RCTs are also included. Mepolizumab was provided at various doses within the 
trials; the doses considered here include the licensed dose of 100mg SC and the 75mg intravenous (IV) 
dose which is considered to be clinically equivalent to 100mg SC.[19]  
 
3.1.2 Key sub-populations 
Effectiveness and cost-effectiveness were assessed for the following post-hoc subgroups of patients 
from the pivotal trials: 
x Intention-to-treat (ITT) population: All trial patients who were randomised and received at 
least one dose of study medication (strictly a modified intention-to-treat population). 
x Company-proposed population: Adult severe refractory eosinophilic asthma patients with a 
EORRGHRVLQRSKLOFRXQWRIFHOOVODWLQLWLDWLRQRIWUHDWPHQWDQGH[DFHUEDWLRQVLQWKH
previous year and/or dependency on mOCS (regardless of exacerbations in previous year). 
x Company-proposed restricted population: Adult severe refractory eosinophilic asthma 
SDWLHQWV ZLWK D EORRG HRVLQRSKLO FRXQW RI  FHOOVO DW LQLWLDWLRQ RI WUHDWPHQW DQG 
exacerbations in the previous year. 
x mOCS users with <4 exacerbations (GHQRWHG³stable mOCS´E\WKH(5*): Adult severe 
UHIUDFWRU\ HRVLQRSKLOLF DVWKPD SDWLHQWV ZLWK D EORRG HRVLQRSKLO FRXQW RI  FHOOVO DW
initiation of treatment and dependency on mOCS but <4 exacerbations in the previous year. 
This constitutes the patients in the company-proposed population who are not within the 
proposed restricted population. 7KH WHUP ³VWDEOH´ LV XVHG IRU HDVH RI UHDGLQJ DQG UHIHUV WR
having fewer than four exacerbations in the previous year. 
x Committee-preferred population: Adult severe refractory eosinophilic asthma patients with 
DEORRGHRVLQRSKLOFRXQWRI300 cells/µl in the previous yearDQGH[DFHUEDWLRQV LQ WKH
previous year and/or dependency on mOCS (regardless of exacerbations in previous year). 
7KHFRPSDQ\¶VUDWLRQDOHIRUWKHproposed population was based on post hoc modelling and subgroup 
analyses of DREAM and MENSA, indicating a greater reduction in exacerbations for mepolizumab 
versus placebo for patients with (a) higher baseline blood eosinophils and (b) more previous 
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exacerbations. In addition, the company included mOCS users with a blood eosinophil level of 
cells/µl in the proposed population (regardless of previous exacerbations) claiming mOCS users are 
likely to be a severe group and that there are clinical benefits to reducing use of mOCS. The company 
also provided data for the proposed restricted population. The ERG requested analyses for the stable 
mOCS population, as the efficacy of mepolizumab in these patients is expected to be lower than in the 
proposed restricted population. The AC proposed an alternative population (termed committee-
preferred population), modifying the eosinophil level threshold in the company-proposed population, 
after concluding that a blood eosinophil level RI300 cells in the previous year was more clinically 
significant of high eosinophil levels than 150 cells/µl at screening. 
3.1.3 Key clinical effectiveness results 
Clinically significant exacerbations were defined in all three trials as worsening of asthma requiring use 
of systemic corticosteroids (or double the maintenance dose) and/or hospitalisation and/or emergency 
department (ED) visits. The rate ratios (RRs) for clinically significant exacerbations for add-on 
mepolizumab versus placebo observed in MENSA, DREAM and SIRIUS are shown in Table 1. 
Table 1: Rate ratios for clinically significant exacerbations for add-on mepolizumab vs. 
placebo (95% CI) observed in MENSA, DREAM and SIRIUS  
Trial 
 
 
Treatment 
arm 
Modified 
ITT 
population 
Proposed 
population 
Proposed 
restricted 
population 
Stable 
mOCS 
Committee-
preferred 
population 
75mg IV 0.53 
(0.39, 0.71) 
0.40 
(0.24, 0.67) 
0.39 
(0.22, 0.68) 
0.45 
(0.16, 1.24) 
0.47 
(0.30, 0.73) 
100mg SC 0.47 
(0.35, 0.63) 
0.50 
(0.32, 0.78) 
0.39 
(0.23, 0.67) 
0.93 
(0.42, 2.03) 
0.56 
(0.37, 0.85) 
75mg IV and 
100mg SC 
0.50 
(0.39, 0.64) 
Not reported Not reported Not reported Not reported 
DREAM  
 
75mg IV 0.52 
(0.39, 0.69) 
0.36 
(0.24, 0.55) 
0.31 
(0.18, 0.53) 
0.41 
(0.19, 0.86) 
0.42 
(0.27, 0.64) 
DREAM + MENSA 
Á  
75mg IV and 
100mg SC 
0.51 
(0.42, 0.62) 
0.41 
(0.31, 0.55) 
0.35 
(0.25, 0.50) 
0.55 
(0.32, 0.92) 
0.47 
(0.36, 0.62) 
SIRIUS  
 
100mg SC 0.68 
(0.47, 0.99) 
0.77 
(0.51, 1.17) 
0.81 
(0.40, 1.64) 
0.75 
(0.44, 1.29) 
0.60 
(0.40, 0.90) 
Abbreviations: IV: intravenous; SC:subcutaneous; ITT:intention-to-treat; mOCS: maintenance oral corticosteroids; 
Analysis of number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline 
maintenance OCS therapy (OCS vs. no OCS), region, and baseline % predicted FEV1, and with logarithm of time on treatment 
as an offset variable. 
ÁSynthesised using random-effects meta-analysis  
 
For exacerbations requiring hospitalisation, RRs for mepolizumab (100mg SC and 75mg IV groups 
combined) vs. placebo, meta-analysed across MENSA and DREAM, were: RR=0.50 (95% CI 0.28, 
0.89) in the modified ITT population; RR=0.44 (95% CI 0.19, 1.02) in the proposed population; 
RR=0.43 (95% CI 0.16, 1.12) in the proposed restricted population; RR=0.53 (95% CI 0.10, 2.75) in 
the stable mOCS population; and RR=0.44 (95% CI 0.18, 1.05) in the committee-preferred population. 
In SIRIUS, hospitalisation numbers were low (ITT: 7 for placebo vs. 0 for mepolizumab). The RRs for 
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exacerbations requiring hospitalisation or ED visits showed a similar pattern to those of exacerbations 
requiring hospitalisation ,Q WHUPV RI TXDOLW\ RI OLIH GLIIHUHQFHV RQ WKH 6W *HRUJH¶V 5HVSLUDWRU\
Questionnaire (SGRQ) for MENSA and SIRIUS for mepolizumab vs. placebo ranged from 5 to 13 units 
(p<0.001 for meta-analysed results) in all sub-populations except stable mOCS (minimal clinically 
important difference [MCID] 4 units). Differences on the Asthma Control Questionnaire (ACQ) meta-
analysed across MENSA and DREAM ranged from -0.3 to -0.8 (p<0.001 for all) across all sub-
populations except stable mOCS (MCID 0.5 units). Differences for the Asthma Quality of Life 
Questionnaire (AQLQ, DREAM only) ranged from 0.1 to 0.4 (MCID 0.5 units) and were not 
statistically significant (p>0.1 for all comparisons). 
3.1.4 Steroid reduction 
The SIRIUS trial had a primary endpoint of percentage reduction in OCS dose whilst maintaining 
asthma control. Odds ratios (OR) for mepolizumab vs. placebo, analysed using a proportional odds 
model for the proportion achieving various categories of reduction in OCS dose whilst maintaining 
asthma control were: OR=2.39 (95% CI 1.25, 4.56) for ITT; OR=1.81 (95% CI 0.86, 3.79) for proposed 
population; OR=2.75 (95% CI 0.72, 10.59) for proposed restricted population; and OR=3.51 (95% CI 
1.69, 7.25) for the committee-preferred population.  
In terms of secondary outcomes in the committee-preferred population, the OCS dose was reduced by 
at least 50% in 57% of patients (mepolizumab) vs. 28% (placebo), resulting in an OR of 3.36 (95% CI 
1.5, 7.52). $UHGXFWLRQLQ2&6GRVHWRPJZDs observed in 56% of patients (mepolizumab) vs. 28% 
(placebo), with an OR of 3.23 (95% CI 1.38, 7.57). In addition, OCS use was stopped completely in 
16% (mepolizumab) vs. 4% (placebo), with an OR of 4.27 (95% CI 0.81, 22.49. ORs were generally 
statistically significant in the modified ITT population. Results were slightly more favourable (in terms 
of magnitude of the point estimates) in the committee-preferred population and in the proposed 
restricted population than the proposed population, but were not statistically significant (p>0.05), 
though patient numbers were small. 
3.1.5 Subgroup analyses 
The company used post hoc subgroup analyses to define the two proposed populations. Two options 
were considered for the HRVLQRSKLO WKUHVKROG ȝ/ DW VFUHHQLQJ RU ȝ/ LQ WKH SUHYLRXV 
PRQWKV3DWLHQWVZLWKȝ/DWVFUHHQLQJKDGDJUHDWHUUHGXFWLRQin exacerbations for mepolizumab 
versus SODFHERWKDQSDWLHQWVZLWKȝ/WKLVZDVQRWWKHFDVHZKHQWKHSRSXODWLon was subgrouped 
XVLQJ D WKUHVKROG RI ȝ/ LQ WKH SUHYLRXV  PRQWKV 7KH FRPSDQ\ XVHd this as the basis for 
IRFXVVLQJRQSDWLHQWVZLWKȝ/DWVFUHHQLQJ,QWHUPVRIH[DFHUEDWLRQKLVWRU\VXEJURXSDQDO\VHV
in DREAM and MENSA suggested that patients with more previous exacerbations had a greater 
reduction in exacerbations for mepolizumab vs. placebo, though the findings were not conclusive. 
Potential issues relating to these sub-populations are discussed in Section 3.2. 
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3.1.6 Open-label extension studies 
The company provided data on two open-label, non-randomised, non-controlled extension studies 
enrolling patients completing the pivotal RCTs. Patients in COSMOS (from MENSA and SIRIUS) 
either continued mepolizumab without interruption or switched from placebo to mepolizumab 100mg 
6& IRU  ZHHNV 3DWLHQWV LQ &2/80%$ IURP '5($0 KDG D --month treatment break and 
subsequently received mepolizumab100mg SC. COLUMBA is ongoing and patients will receive 
mepolizumab for up to 3.5 years. The exacerbation rate per year in COLUMBA was 0.67; this was 
lower than the rate of 1.24 observed in the mepolizumab arm of the modified ITT population in 
DREAM. The rate per year in COSMOS was 0.93; this was similar to the rate of 0.88 observed in the 
MENSA mepolizumab modified ITT population but was higher than the rate of 0.68 observed in the 
SIRIUS trial.  
3.1.7 Indirect comparison of mepolizumab vs. omalizumab 
The company undertook a network meta-analysis (NMA) of trials comparing mepolizumab or 
omalizumab to SoC. The main analysis includes the ITT populations for both mepolizumab and 
omalizumab. Secondary analyses used full-trial populations for omalizumab (as it was not possible to 
obtain data on subgroups within the omalizumab trials) but a subgroup of patients from mepolizumab 
trials who were also eligible for omalizumab (eosinophilic and allergic asthma). Patients in the 
RPDOL]XPDEWULDOVLQWKHPDLQDQDO\VLVZHUHOHVVVHYHUHH[DFHUEDWLRQLQSUHYLRXV\HDUWKDQLQWKH
PHSROL]XPDEWULDOVH[DFHUEDWLRQV7KHPDin analysis compared two double-blind mepolizumab 
RCTs (MENSA and DREAM) with two double-blind omalizumab RCTs (INNOVATE[20] and 
EXTRA[21]). Two additional open-label RCTs of omalizumab were included in secondary analyses 
(Niven 2008[22] and EXALT[23]). 
Based on a fixed-effect NMA undertaken by the company, mepolizumab gave a statistically significant 
reduction in clinically significant exacerbations compared with omalizumab (RR=0.664, 95% credible 
interval (CrI) 0.513, 0.860). Mepolizumab was comparable with omalizumab for exacerbations 
requiring hospitalisation (RR=0.932, 95% CrI 0.350, 2.490) and forced expiratory volume in 1 second 
(FEV1; RR=0.645, 95% CrI -2.652, 3.959). The company notes that results should be treated with 
caution since many trial patients were not eligible for both treatments, and study populations differed 
in severity. Given the heterogeneity between the trials included in the NMA, the ERG considered that 
a random effects model would be more appropriate. A random effects NMA undertaken by the company 
indicates that the reduction in exacerbations is not statistically significant (RR=0.664, 95% CrI 0.283, 
1.498). For exacerbations requiring hospitalisation, the treatment effect observed in the more restricted 
populations favours omalizumab but is not statistically significant. The company concluded that it is a 
reasonable assumption that, in patients who are eligible for both drugs, mepolizumab would be at least 
as effective as omalizumab. 
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3.1.8 Safety of mepolizumab 
In the RCTs, the risk of eczema, nasal congestion and dyspnoea were potentially higher with 
mepolizumab than placebo. Adverse events (AEs) of special interest were: systemic, hypersensitivity 
and injection site reactions; cardiac events; infections; and malignancies. Infusion-related reactions 
were higher for IV (but not SC) mepolizumab than placebo whilst injection site reactions were higher 
for SC (but not IV) mepolizumab (8%) than placebo (3%). Hypersensitivity reactions, infections and 
malignancies occurred at similar rates for mepolizumab and placebo and there were no reports of 
anaphylaxis. Rates of all cardiac events were similar for mepolizumab and placebo, whilst rates of 
serious cardiac events were slightly higher for mepolizumab, though numbers were small. The 
incidence of the following serious AEs was higher for mepolizumab than placebo: herpes zoster (2 vs. 
none); hypertension (2 vs. none); and myocardial ischaemia (2 vs. none). There are few long-term safety 
data. In the RCTs and open-label studies, 5%-6% of patients on mepolizumab 100mg SC developed 
anti-mepolizumab antibodies, which the company claimed did not discernibly impact upon the 
pharmacokinetics and pharmacodynamics of mepolizumab in the majority of patients. Neutralising 
antibodies were detected in one subject. 
3.2 Critique of the Clinical Evidence and Interpretation 
The systematic review process followed by the company was comprehensive and the ERG was 
confident the searches were sufficient to identify all relevant studies of mepolizumab and omalizumab 
for inclusion in the review of clinical effectiveness. Although the ERG considered the evidence 
provided by the company to be generally of good methodological quality, there were a number of 
limitations and uncertainties in the evidence base which warranted caution in its interpretation. 
3.2.1 Limitations of the trials 
Patients were excluded from SIRIUS if they were unable to achieve a stable dose of OCS, which may 
not reflect clinical practice. Trial durations were relatively short (24 to 52 weeks). The primary outcome 
in DREAM and MENSA (clinically significant exacerbations) is a composite outcome including the 
requirement for systemic OCS (or double maintenance dose) and/or hospitalisation and/or ED visits. 
3.2.2 Statistical justification for the sub-populations 
The post hoc subgroup and modelling analyses used to justify the FRPSDQ\¶Vproposed populations 
should be interpreted with caution. Multivariate modelling of DREAM data showed that patients with 
DEORRGHRVLQRSKLOFRXQWFHOOV/DWVFUHHQLQJKDGDUHGXFWLRQLQUDWHRIH[DFHUEDWLRQVIRU
mepolizumab vs. placebo; however, the uncertainty associated with the predicted rate reduction is not 
clear. The blood eosinophil threshold giving a 30% reduction in exacerbations varies between DREAM 
and MENSA and by number of previous exacerbations. The FRPSDQ\¶V VXEPLVVLRQ compares two 
RSWLRQVIRUDEORRGHRVLQRSKLOWKUHVKROGȝ/DWVFUHHQLQJRUȝ/LQWKHSUHYLRXVPRQWKV 
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3.2.3 Clinical validity of sub-populations 
The company claims that the thresholds for eosinophil level and previous exacerbations were clinically 
plausible and practical to implement according to severe asthma specialists. In terms of eosinophil level, 
the European Medicines Agency concluded that eosinophil levels were not sufficiently predictive to 
justify a specific cut-off within their marketing authorisation. The ERG believed that the blood 
eosinophil count RIFHOOV/ at screening is not a valid criterion to find a population in which 
mepolizumab is more effective in the medium- and long-term for two reasons: 1) EHFDXVHȝ/LV, 
according to clinicians, within the normal range and; 2) because eosinophil levels can fluctuate. Due to 
the uncertainties around the subgroup analyses combined with the fact that a threshold of cellsȝ/
in the previous 12 months was considered by clinicians and the committee to be more clinically relevant 
WKDQȝ/DWVFUHHQLQJ, the former was used in the definition of the committee-preferred population. 
&OLQLFDODGYLVRUVWRWKH(5*FRQVLGHUHGWKDWDWKUHVKROGRISUHYLRXVH[DFHUEDWLRQVZDVFOLQLFDOO\
appropriate, and was consistent with NICE guidance for omalizumab which restricts the use of the drug 
WR SHRSOH UHTXLULQJ FRQWLQXRXV RU IUHTXHQW WUHDWPHQW ZLWK RUDO FRUWLFRVWHURLGV  FRXUVHV LQ WKH
previous year). 
3.2.4 Evaluation of the indirect comparison 
The indirect comparison methods appeared broadly appropriate. However, the ERG considered that the 
results of the random effects model provided a more appropriate (and more conservative) estimate than 
those of the fixed effects model given the heterogeneity between trials. The company further 
acknowledged that the results should be treated with caution since only a small proportion of patients 
in the mepolizumab and omalizumab trials were eligible for both treatments, and study populations 
differed in terms of severity. 
3.3 Cost-Effectiveness Evidence 
The company conducted a systematic review on the cost-effectiveness of interventions for the treatment 
of severe eosinophilic asthma with mepolizumab. No suitable studies were found; therefore the 
company developed a de novo economic model, implemented in Microsoft Excel®, to estimate the cost-
effectiveness of add-on mepolizumab compared with SoC and omalizumab.  
The model employed a Markov cohort simulation approach. The perspective used was that of the NHS. 
The starting age of the cohort was set 50.1 years, the cycle length to four weeks and a lifetime time 
horizon was used.  A discount rate of 3.5% per annum was used both for costs and utilities. The model 
includes four states: (i) on-treatment before continuation assessment; (ii) on-treatment after 
continuation assessment; (iii) off-treatment and; (iv) death. All patients on mepolizumab or omalizumab 
WUHDWPHQW HQWHU WKH PRGHO LQ WKH µRQ-WUHDWPHQW EHIRUH FRQWLQXDWLRQ DVVHVVPHQW¶ VWDWH XQWLO WKH
continuation assessment. After continuation assessment, pDWLHQWVWUDQVLWLRQHLWKHUWRµRQ-treatment after 
13 
 
FRQWLQXDWLRQDVVHVVPHQW¶RUµRII-WUHDWPHQW¶GHSHQGLQJRQZKHWKHURUQRWWKH\PHHW the continuation 
criteria: patients on mepolizumab continued on treatment unless the exacerbation rate worsened 
compared with WKHSUHYLRXV3DWLHQWVLQWKHµRQ-WUHDWPHQWDIWHUFRQWLQXDWLRQDVVHVVPHQW¶VWDWHWUDQVLWLRQ
WRWKHµRII-WUHDWPHQW¶VWDWHZKHQWKH\GLVFRQWLQXHWUHDWPHQWTreatment discontinuation might happen 
either due to natural attrition or by reaching the end of the treatment duration, which in the base case 
was assumed to be 10 years. $OOSDWLHQWVRQ6R&HQWHUWKHPRGHOLQWKHµRII-WUHDWPHQW¶VWDWH'XULQJ
any cycle, patients can transition from any of the alive states to death as a consequence of either asthma-
related mortality (ARM) following an exacerbation or due to other causes. 
The effectiveness of mepolizumab was reflected in a reduction of exacerbation rates and in a better 
health-related quality of life (HRQoL). All exacerbation rates were initially calculated from the 
MENSA trial for both arms, mepolizumab and SoC. Different exacerbation rates were used before and 
after the continuation assessment to reflect the lower exacerbation rates of responders. The exacerbation 
rate for patients continuing on mepolizumab after the continuation assessment was assumed to be equal 
to that observed in patients meeting the continuation criteria during MENSA. The exacerbation rate for 
patients who discontinued mepolizumab was assumed to increase to that of patients on SoC. 
ThHFRPSDQ\¶VPRGHOassumed that ARM occurs only following a clinically significant exacerbation. 
In the base case analysis, the mortality rates after clinically significant exacerbations were based on two 
sources: Watson et al.[24] and the National Review of Asthma Deaths (NRAD) report.[7] The company 
assumed that the deaths reported in Watson et al. were those happening in hospital, which according to 
the NRAD report only account for the 30% of asthma-related deaths.  Therefore, the total number of 
deaths was assumed to be 100/30 times greater than those reported in Watson et al. The probability of 
death after hospitalisation according to Watson et al. is 0.0038 for people aged 18 to 44 years and 
0.0248 for people aged 45 years or older. After consultation, the company undertook a retrospective 
cohort analysis using the same database as the one used to inform Watson et al. (the CHKS database). 
but applying Roberts et al¶VDJHVWUDWLILFDWLRQ-54, 55-64 and 65. 
Utility values were obtained from two sources. EQ-5D scores were captured at 4-weekly intervals in 
the DREAM trial. However, in the MENSA and SIRIUS trials, the SGRQ was used. The base case uses 
EQ-5D scores mapped from the SGRQ scores measured in the MENSA trial instead of the direct EQ-
5D data captured within DREAM. The mapping from SGRQ scores to EQ-5D scores was performed 
using an algorithm proposed by Starkie et al.[25] to predict EQ-5D utility from the SGRQ in subjects 
with COPD. The company justified the use of SGRQ-mapped scores FODLPLQJ³EQ-5D did not capture 
the granularity in HRQoL of people with severe asthma´ Similarly to exacerbation rates, the company 
used different utility values before and after continuation assessment to reflect the higher HRQoL of 
responders. The utility value for patients on mepolizumab until continuation assessment was calculated 
based on all patients whilst the utility value for patients continuing mepolizumab after continuation 
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assessment was calculated based solely on the patients meeting the continuation criteria. The utility 
value for patients discontinuing mepolizumab after continuation assessment was assumed to drop to 
that of patients on SoC. During consultation, the company revealed that there was a baseline imbalance 
on the average EQ-5D values between patients on mepolizumab and SoC and presented baseline-
adjusted utility values. ([DFHUEDWLRQVZHUHDVVXPHGWRKDYHDQLPSDFWRQWKHSDWLHQWV¶+54R/7KH
disutility values and their duration were based on a study by Lloyd et al.[26] For the duration of 
disutilities however, the company accepted after consultation to use the midpoint between the average 
exacerbation durations as measured in MENSA and the duration of the  Lloyd et al.[26] study, as 
explained in Section 3.4. 
As explained in Section 3.1, the company conducted an NMA to calculate the exacerbation RRs for 
mepolizumab and omalizumab compared with SoC. The resulting mean exacerbation RRs compared 
with SoC were 0.496 for mepolizumab and 0.746 and omalizumab. These RRs were applied only to the 
period before continuation assessment due to the differences in the continuation criteria between the 
two treatments: patients continued on mepolizumab unless the exacerbation rate worsened whilst 
patients on omalizumab continued only if they achieved a score of good or excellent in the global 
evaluation of treatment effectiveness (GETE). After continuation assessment, for mepolizumab the 
same exacerbation rate used in the base case was used, whilst for omalizumab the exacerbation rate  
observed in omalizumab responders during the INNOVATE trial [20] (0.373) was used.  
The cost of mepolizumab used in the model included the Patient Access Scheme (PAS) proposed by 
the company. The list price reported in the British National Formulary (BNF)[27] was used for 
omalizumab, as directed by NICE, although a commercial-in-confidence PAS is in place. Instead of 
using the cost of the omalizumab treatment used in the recent omalizumab multiple technology 
assessment (MTA), [28] the company undertook a study to estimate the cost of the omalizumab 
treatment in clinical practice. The calculation of the average cost of the omalizumab treatment is not 
straightforward because the frequency and dosage of the injections GHSHQGRQWKHSDWLHQW¶VZHLJKWDQd 
serum IgE levels. The company-led study concluded that the annual cost of the omalizumab treatment 
was considerably higher (£11,370) than the one calculated based on the INNOVATE trial and used in 
the omalizumab MTA (£8,056). Unit costs for administration and monitoring costs were taken from the 
PSSRU,[29] and NHS Reference Costs 2013/2014,[30] whilst drug costs for SoC were taken from BNF. 
[27] Costs were updated when necessary to 2014 values using the health service cost index (HCHS).[29] 
In their original base case analysis, the company estimated that the probabilistic incremental cost-
effectiveness ratio (ICER) for add-on mepolizumab versus SoC was £19,511 per quality-adjusted life 
year (QALY) gained in their proposed population, and £15,478 per QALY gained in their proposed 
restricted population. As the appraisal progressed, the definition of the target population changed as did 
the PAS offered by the company, the continuation criteria, asthma-related mortality rates, exacerbation 
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rates and utility values, based to a large extent on the reasoning presented in Section 3.4. The final ICER 
presented by the company for add-on mepolizumab compared with SoC for the committee-preferred 
population and continuation criteria was £27,418 per QALY gained. $OODQDO\VHV LQ WKHFRPSDQ\¶V
submission used the PAS for mepolizumab. 
%DVHGRQWKHOLVWSULFHIRURPDOL]XPDEWKHFRPSDQ\¶VDQDO\VLVconcluded that mepolizumab dominates 
omalizumab as it is estimated to be less expensive and more effective. Mepolizumab dominates 
omalizumab in all the sensitivity analyses undertaken by the company. The validity of this results is 
limited due to the existence of a PAS in place for omalizumab. 
 
3.4 Critique of the Cost-Effectiveness Evidence and Interpretation 
The mathematical model submitted by the company was conceptually reasonable and complete and had 
only a few minor implementation errors.  
 
3.4.1 Continuation criteria 
The original continuation criteria proposed by the company (i.e. continue on treatment unless the 
exacerbation rate increases compared to the previous year) implied that a subgroup of patients could 
remain on treatment even when experiencing no improvement. The company argued that some patients 
could benefit from a OCS dose reduction whilst maintaining asthma control. The appraisal committee 
consequently proposed continuation criteria as follows: a reduction of at least 50% in exacerbation rate 
and/or a clinically significant reduction in mOCS dose while maintaining or improving asthma control. 
The ERG noted that the ICERs calculated in the appraisal only reflected the cost-effectiveness of 
patients whose exacerbation rate was reduced at least 50%, since the effectiveness estimates were based 
on trials where an mOCS dose reduction was not allowed. The ERG notes that the ICER for 
mepolizumab versus SoC in patients whose mOCS dose is reduced but whose exacerbation rate is 
maintained is likely to be higher than that of patients whose exacerbation rate was reduced at least 50%. 
This is due to an important part of the treatment benefit coming from exacerbation reduction. 
3.4.2 Inclusion of the mOCS users with <4 exacerbations in the proposed population 
The difference in the estimated ICERs per QALY gained between the proposed population and the 
proposed restricted population suggest that the use of mepolizumab in mOCS users with <4 
exacerbations PD\KDYHDKLJK,&(5,QUHVSRQVHWRWKH(5*¶VFODULILFDWLRQTXHVWLRQVWKHFRPSDQ\
undertook a scenario analysis for this sub-population that resulted in an ICER of £78,716 per QALY 
gained, based on the FRPSDQ\¶Voriginal analysis and original PAS price.  
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3.4.3 Exacerbation rates after continuation assessment 
The exacerbation rates used in the model were calculated by dividing the number of exacerbations by 
the number of person-years of exposure in the MENSA trial. Those for patients continuing treatment 
after continuation assessment were calculated based on the data from Week 16 to the end of the trial 
(Week 32) in patients that met the continuation criteria at the end of MENSA. This is not ideal for three 
reasons: (i) the future rates of asthma observed in patients who met the continuation criteria (which was 
a non-worsening of the exacerbation rate) are likely to be higher than the rates observed due to 
regression to the mean; (ii) the exacerbation rate is measured during a short period (16 weeks), which 
results in uncertainty, and; (iii) measurements may be subject to potential inaccuracy due to the seasonal 
nature of asthma exacerbations. The ERG proposed instead to use the exacerbation rates observed in 
the COSMOS open label extension trial in patients who met the continuation criteria in MENSA and 
went on to participate in COSMOS. The appraisal committee agreed with this proposal and the company 
provided the relevant rates from COSMOS. The ERG also noted that patients on mepolizumab who did 
not meet the continuation criteria were by definition the most severe patients and therefore it was not 
reasonable to assume they would go on to have the average exacerbation rate observed in SoC.  The 
committee agreed and the company provided the exacerbation rates of patients observed in COSMOS 
in patients who had failed the continuation criteria in MENSA, which were higher than those observed 
in SoC in MENSA. 
3.4.4 Asthma-related mortality (ARM) 
The company used ARM rates reported by Watson et al.[24] and the relative rates of ARM outside of 
hospital reported in the NRAD report.[7] The ERG noted that Watson et al. used a constant rate of 
ARM for those aged 45 years and over. However, the age stratification in Roberts et al. indicates that 
the rate of ARM is approximately six times higher in the 65 years and over group than that in the 45-
54 years age group. The ERG noted that there is no evidence to believe this proportion was not 
applicable to severe asthma patients. Therefore, the ARM rate for those aged 45 years and over in 
Watson et al. is likely to overestimate mortality between the ages of 45 and 65 and underestimate it 
above the age of 65 years. This, in turn would overestimate the benefits of a reduction in ARM, as early 
deaths have a bigger impact than late deaths. After consultation, the company undertook a retrospective 
cohort analysis using the same database as the one used to inform Watson et al. but applying Roberts 
et al¶VDJHVWUDWLILFDWLRQ: 45-54, 55-64 and 65. As expected, the mortality rate in the 45-54 age range 
was much lower (0.0092) than that in the 65 age range (0.0455). The ICERs for add-on mepolizumab 
compared with SoC as calculated by the company increased when using the ARM rates with the new 
age-stratification instead of that in Watson et al. [24] 
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3.4.5 Utility values 
The company claimed that the EQ-5D suffered from a ceiling effect and poor sensitivity in severe 
asthma. Therefore, the company used an alternative instrument, the SGRQ, and mapped to the EQ-5D 
using an algorithm proposed by Starkie et al.[25] to predict EQ-5D utility from the SGRQ in subjects 
with COPD. The ERG noted that it is uncertain to what extent the mappings obtained using data from 
COPD rather than asthma could influence the results. Furthermore, if the mapping algorithm correctly 
predicts EQ-5D scores of patients with severe asthma, then the mapping would not address the claimed 
deficiencies of the EQ-5D. The ERG believed that the directly measured EQ-5D values were preferable 
to mapped EQ-5D estimates, with which the committee agreed. Therefore, directly measured EQ-5D 
values were used in the rest of the appraisal. In a similar way as with exacerbation rates, the company 
assumed that the utility value of those patients failing to meet the continuation criteria and discontinuing 
mepolizumab would drop to that of the average of patients on SoC. The ERG noted that the subgroup 
of patients failing the continuation criteria was likely to be the most severe subgroup and calculated the 
adjusted utilities for this subgroup based on the average utility for patients on mepolizumab and the 
average utility of patients on mepolizumab who met the continuation criteria. 
3.4.6 Duration of disutility from exacerbations 
The company assumed that the disutilities reflecting the impact on the HRQoL of exacerbations 
reported in Lloyd et al.[26] would last for 28 days, based on the length of the Lloyd et al.[26]  study. 
The ERG considered that using the duration of the exacerbations as measured in MENSA would be 
more appropriate. The company argued then that the disutility due to an exacerbation could last longer 
than its measured length in terms of OCS burst or hospital stay. The ERG acknowledged that there is 
potential for the duration of the disutility from exacerbations to be underestimated using only the 
average length of exacerbations in MENSA. Consequently, the company and the ERG agreed that using 
the midpoint between the mean duration of exacerbations in MENSA and the length of the Lloyd et 
al.[26] study was a reasonable compromise.  
3.4.7 OCS sparing 
The FRPSDQ\¶V VXEPLVVLRQ included a scenario analysis that took into account the costs and 
consequences of long-term systemic OCS usage. This analysis had several limitations: (i) it used OCS 
VSDULQJGDWD IURP WKH ,77SRSXODWLRQRI6,5,86 LQVWHDGRI WKHFRPSDQ\¶VSURSRVHG or committee-
preferred populations; (ii) it used OCS sparing estimates from SIRIUS whilst using exacerbation 
reductions observed in MENSA; (iii) the time horizon considered was 10 years instead of lifetime costs 
and utility decrement from fractures (resulting from osteoporosis) were not considered; (iv) some utility 
decrements estimated as chronic conditions were considered as one-off disutilities, and; (v) neither the 
proportion of the cohort that was alive at each cycle was considered to calculate the incidence of AEs 
nor the patients that suffered chronic disutilities from AEs that died were accounted for. The company 
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acknowledged and the ERG agreed that WKHFRPSDQ\¶V analysis did not appropriately capture the long-
term benefits of OCS reduction.  
3.4.8 Comparison with omalizumab 
The cost of omalizumab used within the MTA was considered by the ERG to be more appropriate than 
WKDWRIWKHFRPSDQ\¶VVWXG\EHFDXVHLWUHVXOWHGLQcosts and efficacy data deriving from the same source. 
The ERG noted that the NICE guidance recommends omalizumab only for patients on ³FRQWLQXRXVRU
IUHTXHQW WUHDWPHQW ZLWK RUDO FRUWLFRVWHURLGV´[28].  The ERG believes that omalizumab should be 
compared to mepolizumab in the population in which omalizumab is recommended. The company used 
the exacerbation RR of omalizumab for the ITT population (0.373) instead of the one reported for the 
mOCS subgroup (0.293).[31] Finally, the ERG believed that using a random effects model to calculate 
the exacerbation RR for patients before continuation assessment was more appropriate for the NMA 
than the fixed effects model used by the company. 
3.5 Additional Work Undertaken by the Evidence Review Group 
The ERG undertook additional analyses using different assumptions to those made by the company in 
their base case. These analyses informed the AC and led to new analyses by the company. The list of 
alternative assumptions used by the ERG that were incorporated to the FRPSDQ\¶V revised base case is 
as follows:  
1) Using the exacerbation rates observed in the COSMOS open-label extension study for patients 
on mepolizumab after continuation assessment.  
2) Use of directly measured EQ-5D scores instead of the scores mapped from SGRQ;  
3) Use of alternative ARM rates. First using the rates combining the data from Watson et al.[24] 
and Roberts et al.[32] and after consultation using WKRVH FDOFXODWHG LQ WKH FRPSDQ\¶V
retrospective cohort study;  
4) Using the duration of disutility due to exacerbations equal to the mid-point of the length of 
exacerbations measured in MENSA and the length of the Lloyd et al.[26] study. 
 
The ERG applied the following FKDQJHVWRWKHFRPSDQ\¶VUHYLVHGEDVHFDVH 
1) Use of age-adjusted utilities, as per Ara and Brazier.[33] 
2) Use of the attrition rate calculated on the committee-preferred population instead of ITT 
population. 
3) Use of average age at start from committee-preferred population (51.5 years) instead of ITT 
population (50.1 years). 
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4) Use of the correct percentage of patients meeting the continuation criteria in the committee-
preferred population (the company had made a minor error which was acknowledged upon 
clarification request). 
After applying these FKDQJHVWRWKHFRPSDQ\¶VUHYLVHGEDVH case, the ICER for mepolizumab compared 
with SoC increased from £27,418 to £29,163 per QALY gained. These ICERs were calculated based 
on continuation criteria according to which patients on mepolizumab would discontinue treatment after 
one year unless their number of exacerbations was reduced by at least 50% or their mOCS dose was 
reduced whilst maintaining asthma control. However, patients were not allowed to reduce their mOCS 
dose in the trials that served as evidence source for the treatment efficacy. Therefore, the ICER for 
patients who fail to achieve a 50% reduction in the number of exacerbations but continue on treatment 
due to a reduction in mOCS dose whilst maintaining asthma control is uncertain. The ERG estimated 
the ICER of mepolizumab versus SoC for these patients to be £60,825 per QALY, by assuming that 
these patients would have the same reduction in exacerbations as that observed in the MENSA RCT in 
patients on SoC (50.4%). This ICER does not take the benefits of avoiding long-term mOCS side-effects 
into account, but the ERG notes that it is unlikely that taking these benefits into account would drive 
the ICER under the threshold of £30,000 per QALY. 
The ERG undertook exploratory analyses assessing the impact of different continuation criteria, 
different average age at treatment start and a potential waning effect. The ICER for mepolizumab 
compared with SoC increased from £29,163 to £31,378 and to £31,895 per QALY, when the 
continuation criterion threshold for reduction in exacerbations was lowered from 50% to 30% and 0% 
respectively. The ERG argued that if mepolizumab were to be recommended, the average age at 
treatment start would be lower than that observed in the trials because patients would start on 
mepolizumab soon after their asthma was uncontrolled in step 4 (high dose ICS plus additional 
maintenance treatments and short courses of OCS). The ERG estimated that the ICER of mepolizumab 
would increase from £29,163 to £32,557 and to £39,761 per QALY if the average age at treatment 
initiation was 45 and 40 years respectively instead of the 51.5 years observed in the trial. The AC 
considered a hypothetical waning effect in the treatment efficacy. The company argued that there was 
no evidence of a waning effect and that the mechanism of action of the drug did not justify a waning 
effect. However, in the absence of long term effectiveness data, the ERG presented results of 
exploratory analyses that showed that the ICER of add-on mepolizumab versus SoC would increase 
from £29,163 to £34,744 and to £43,429 per QALY if treatment effect was assumed to wane linearly 
until losing all its effect in 30 and 10 years respectively. 
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3.6 Conclusions of the Evidence Review Group Report 
The evidence submitted by the company is consistent with the NICE scope for interventions, 
comparators and relevant outcomes. The ERG was satisfied that the final definition of the relevant 
population included the EORRGHRVLQRSKLOFRXQWRI0 cells/µl in the previous year instead of the 
cells/µL at screening7KHFULWHULRQRIH[DFHUEDWLons in the previous year appeared more clinically 
robust than a dependency on mOCS.  
The ERG noted that the AC shared its preference for using the exacerbation rates from the COSMOS 
extension study as well as that it adopted the adjustments in the exacerbation rates and utilities for non-
responders and the mortality rates based on more accurate age stratification. However, the ERG noted 
that the ICERs used by the AC in its decision to recommend add-on mepolizumab were based on part 
of the relevant population only. The continuation criteria establish that patients who have not achieved 
a 50% reduction in the number of exacerbations can still continue on treatment if their dose of mOCS 
is reduced whilst maintaining asthma control. However, the trials in which the treatment effect was 
measured did not allow a reduction in mOCS dose. The ERG believes that the ICER for this subgroup 
is higher than that reflected in the FAD. 
4. Key Methodological Issues 
The best way to define the relevant population in terms of severity of asthma and degree of eosinophilia 
was unclear. The severity of asthma was defined by the company in terms of number of exacerbations 
in the previous year and/or dependency on mOCS. The company argued that patients on mOCS were 
especially severe cases regardless of the number of exacerbations. The ERG noted that mepolizumab 
was likely to be less cost-effective in patients on mOCS who had less than 4 exacerbations in the 
previous year. The level of eosinophilia was defined by the company using a blood eosinophil count of 
 cells/µl at screening. The ERG, advised by its clinical experts, argued against this criterion 
because EORRGHRVLQRSKLO OHYHOV IOXFWXDWHGRYHU WLPHDQGD OHYHORIEORRGHRVLQRSKLOFRXQWRI 
cells/µl is well within the normal range. Consequently, the AC preferred to use a level of blood 
eosinophiOFRXQWRI cells/µl in the previous year to define the relevant population. 
7KH FRPSDQ\¶V HFRQRPLF PRGHO was based on an analysis of responders and non-responders. The 
company assumed that non-responders would have a disease progression similar to those on SoC. 
However, the ERG pointed out that if the responders are individuals with a better prognosis, then the 
non-responders would have a worse prognosis than the average patient in the control arm. The ERG 
consequently applied adjustments for the exacerbation rates and the utilities of non-responders. 
The company tried to include the benefits of mOCS sparing in their model. It is well known that the 
long-term use of mOCS has important side effects. However, it is difficult to capture these side effects, 
as they affect the likelihood of a patient developing a myriad of conditions. The company included 
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cataracts, myocardial infarction, peptic ulcer and osteoporosis in their analysis, but these are only a 
subset of the conditions affected by the long term use of mOCS. In addition, it is complicated to estimate 
how a partial reduction of the mOCS dose affects the incidence of these side effects. Further research 
on this topic would be of high interest given the prevalence of OCS in current practice. 
Finally, the continuation criteria included a condition that was not observed in the trials used to estimate 
treatment efficacy, i.e. the reduction in mOCS dose. In the absence of evidence on how the reduction 
of mOCS would affect the treatment effect in these trials, the ERG and the AC were forced to estimate 
the ICER for this subgroup based on other trials. 
5. National Institute for Health and Care Excellence Guidance 
In December 2016, following three AC meetings, on the basis of the evidence available (including 
verbal testimony of invited clinical experts and patient representatives), the AC produced guidance that 
add-on mepolizumab was recommended as an option for treating severe refractory eosinophilic asthma 
in adults, only if the blood eosinophil count is 0 cells/µl in the previous 12 months; and the patient 
has had 4 or more exacerbations in the previous year or has been on mOCS over the previous 6 months. 
The AC established that mepolizumab should be discontinued unless the number of exacerbations was 
UHGXFHGE\RUa clinically significant reduction in mOCS use was achieved while maintaining or 
improving asthma control. The recommendation was conditional on the company providing 
mepolizumab with the agreed PAS. 
5.1 Consideration of Clinical and Cost-Effectiveness Issues Included in the Final Appraisal 
Determination  
The full list of the issues considered by the Appraisal Committee can be found in the FAD.[34] The key 
issues are described in the following sections.  
5.1.1 Current Clinical Management 
The AC considered the current clinical management of severe eosinophilic asthma in England and noted 
that it follows guidelines from the British Thoracic Society and Scottish Intercollegiate Guidelines 
Network (SIGN). The clinical experts explained that the management of severe eosinophilic asthma lies 
within what was previously known as step 4 and step 5 of the superseded 2014 version of the British 
Thoracic Society and SIGN guidelines. The current guidelines (2016) indicate that those people having 
high-dose therapies (previously step 4) or continuous or frequent use of oral steroids (previously step 
5) should be referred for specialist care. The AC understood that oral systemic corticosteroids are used 
either for short periods to manage an exacerbation, or for longer periods as maintenance treatment when 
it is difficult to wean people off corticosteroids without an increase in exacerbations. The AC concluded 
that in clinical practice in the NHS, people with severe refractory eosinophilic asthma who have adhered 
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to an optimised standard treatment plan (that is high-dose therapies [previously step 4], or continuous 
or frequent use of oral corticosteroids [previously step 5]) might be offered mepolizumab by a specialist. 
5.1.2 Uncertainties in the Clinical evidence 
The AC concluded that the comparison of mepolizumab with omalizumab was not clinically relevant 
or methodologically robust and therefore did not consider this comparison further.  
5.1.3 Uncertainties in the Economic Modelling  
The AC noted that the ICER was higher when the age of onset of treatment was lower. The AC 
concluded that there was some evidence to suggest that the age of onset of treatment was lower than 
WKHFRPSDQ\¶VHVWLPDWHDQGDJUHHGWRWDNHWKLVLQWRDFFRXQWZKHQPDNLQJLWVGHFLVLRQ 
The committee recognised the challenges in modelling the benefits of reducing mOCS, and therefore 
also a related continuation rule. 
6. Conclusion 
The NICE AC considered WKH(5*¶V,&(5 of £29,163 per QALY, but acknowledged that the ICER 
would be higher (£32,557 per QALY), if patients were younger (45 years) at treatment start than the 
mean age in the relevant subgroup in the trial (51.5 years), or lower if the adverse effects associated 
with the long-term use of systemic corticosteroids were accounted for. The AC therefore concluded that 
mepolizumab, as an add-on to SoC, could be recommended as an option for treating severe refractory 
eosinophilic asthma in adults who had had 4 or more exacerbations in the previous year and/or 
dependency on mOCS, DQGDEORRGHRVLQRSKLOFRXQWRI0 cells/µl in the previous year, if patients 
discontinued treatment after a year unless a reduction in the number of exacerbations of at least 50% 
was achieved or systemic corticosteroids use was reduced whilst maintaining asthma control. 
  
23 
 
Acknowledgements 
This summary of the ERG report was compiled after NICE issued the FAD. All authors have 
commented on the submitted manuscript and have given their approval for the final version to be 
published. The views and opinions expressed therein are those of the authors and do not necessarily 
reflect those of NICE or the Department of Health. Any errors are the responsibility of the authors. 
 
Author contributions  
Katy Cooper, Sue Harnan, and Christopher Carroll critiqued the clinical effectiveness data reported by 
the company. Iñigo Bermejo and Matt Stevenson critiqued the mathematical model provided and the 
cost-effectiveness analyses submitted by the company. Jean Hamilton critiqued the network meta-
analysis performed by the company. Mark Clowes critiqued the literature searches conducted by the 
company. Tim Harrison and Shironjit Saha provided clinical advice to the ERG throughout the project. 
All authors were involved in drafting and commenting on the final document. Iñigo Bermejo acts as the 
guarantor of the manuscript. This summary has not been externally reviewed by PharmacoEconomics. 
 
Compliance with Ethical Standards 
Funding 
This project was funded by the National Institute for Health Research (NIHR) Health Technology 
Assessment Programme (Project Number 15/06/06). See the HTA programme website for further 
project information (http://www.hta.ac.uk). 
Conflicts of Interest 
Tim Harrison received personal payments for an advisory board from GSK after the completion of the 
work described in this paper. IB, MS, KC, SH, JH, MC, CC and SS have no potential conflicts of interest 
that are directly relevant to the content of this article. 
 
  
24 
 
References 
1. National Institute for Health and Care Excellence. Guide to the methods of technology 
appraisal 2013. 2013; Available from: https://www.nice.org.uk/article/pmg9/. 
2. Stevenson, M., et al. Mepolizumab for treating severe eosinophilic asthma: A Single 
Technology Appraisal. School of Health and Related Research. (ScHARR). 2016; Available 
from: https://www.nice.org.uk/guidance/ta431/documents/committee-papers. 
3. National Institute for Health and Care Excellence. Mepolizumab for treating severe refractory 
eosinophilic asthma. 2017; Available from: https://www.nice.org.uk/guidance/ta431. 
4. Boulet, L.-P., Irreversible airway obstruction in asthma. Current Allergy and Asthma 
Reports, 2009. 9(2): p. 168-173. 
5. BTS/SIGN. SIGN 141 British guideline on the management of asthma. 2014; Available from: 
https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-
asthma-guideline-2014/. 
6. Chung, K.F., et al., International ERS/ATS guidelines on definition, evaluation and treatment 
of severe asthma. Eur Respir J, 2014. 43(2): p. 343-73. 
7. Royal College of Physicians. Why asthma still kills: The National Review of Asthma Deaths 
(NRAD). 2014; Available from: https://www.rcplondon.ac.uk/sites/default/files/why-asthma-
still-kills-full-report.pdf. 
8. Walford, H.H. and T.A. Doherty, Diagnosis and management of eosinophilic asthma: a US 
perspective. J Asthma Allergy, 2014. 7: p. 53-65. 
9. Good, J.T., Jr., et al., Refractory asthma: importance of bronchoscopy to identify phenotypes 
and direct therapy. Chest, 2012. 141(3): p. 599-606. 
10. Silkoff, P.E., et al., Exhaled nitric oxide identifies the persistent eosinophilic phenotype in 
severe refractory asthma. J Allergy Clin Immunol, 2005. 116(6): p. 1249-55. 
11. Mahr, T.A., J. Malka, and J.D. Spahn, Inflammometry in pediatric asthma: a review of 
fractional exhaled nitric oxide in clinical practice. Allergy Asthma Proc, 2013. 34(3): p. 210-
9. 
12. Barnes, P.J., et al., Exhaled nitric oxide in pulmonary diseases: a comprehensive review. 
Chest, 2010. 138(3): p. 682-92. 
13. GSK. GSK receives European marketing authorisation for Nucala® (mepolizumab) in 31 
countries. 2015; Available from: https://www.gsk.com/en-gb/media/press-releases/2015/gsk-
receives-european-marketing-authorisation-for-nucala-mepolizumab-in-31-countries. 
14. Pavord, I.D., et al., Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, 
double-blind, placebo-controlled trial. Lancet, 2012. 380(9842): p. 651-9. 
15. Ortega, H.G., et al., Mepolizumab treatment in patients with severe eosinophilic asthma. New 
England Journal of Medicine, 2014. 371(13): p. 1198-1207. 
16. Bel, E., et al., Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. 
NCT01691508. N Engl J Med, 2014. 371: p. 1189-1197. 
17. Lugogo, N., et al., Long-term Efficacy and Safety of Mepolizumab in Patients With Severe 
Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. Clinical Therapeutics, 
2016. 38(9): p. 2058-2070.e1. 
18. GlaxoSmithKline. MEA112997 Open-label Long Term Extension Safety Study of 
Mepolizumab in Asthmatic Subjects. 2017; Available from: 
https://clinicaltrials.gov/ct2/show/NCT01691859. 
19. European Medicines Agency. EPAR summary for the public.  Nucala Mepolizumab. 
European Public Assessment Report (EPAR), 2015; Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Summary_for_the_public/human/003860/WC500198039.pdf. 
20. Humbert, M., et al., Benefits of omalizumab as add-on therapy in patients with severe 
persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 
step 4 treatment): INNOVATE. Allergy, 2005. 60(3): p. 309-16. 
21. Hanania, N.A., et al., Omalizumab in severe allergic asthma inadequately controlled with 
standard therapy: a randomized trial. Ann Intern Med, 2011. 154(9): p. 573-82. 
25 
 
22. Niven, R., et al., Effectiveness of omalizumab in patients with inadequately controlled severe 
persistent allergic asthma: an open-label study. Respir Med, 2008. 102(10): p. 1371-8. 
23. Bousquet, J., et al., Persistency of response to omalizumab therapy in severe allergic (IgE-
mediated) asthma. Allergy, 2011. 66(5): p. 671-8. 
24. Watson, L., et al., Factors associated with mortality after an asthma admission: A national 
United Kingdom database analysis. Respiratory Medicine, 2007. 101(8): p. 1659-1664. 
25. Starkie, H.J., et al., Predicting EQ-5D Values Using the SGRQ. Value in Health, 2011. 14(2): 
p. 354-360. 
26. Lloyd, A., D. Price, and R. Brown, The impact of asthma exacerbations on health-related 
quality of life in moderate to severe asthma patients in the UK. Primary Care Respiratory 
Journal, 2007. 16: p. 22. 
27. British National Formulary. BNF June 2015. 2015; Available from: www.bnf.org/. 
28. National Institute for Health and Care Excellence. Omalizumab for treating severe persistent 
allergic asthma.  NICE technology appraisal guidance [TA278]. 2013; Available from: 
https://www.nice.org.uk/guidance/TA278. 
29. Personal Social Services Research Unit, Unit Costs of Health and Social Care. 2015. 
30. Department of Health. NHS reference costs 2013 to 2014. 2015; Available from: 
https://www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014. 
31. Norman, G., et al., Omalizumab for the treatment of severe persistent allergic asthma: a 
systematic review and economic evaluation. Health Technol Assess, 2013. 17(52). 
32. Roberts, N.J., et al., Time trends in 30 day case-fatality following hospitalisation for asthma 
in adults in Scotland: A retrospective cohort study from 1981 to 2009. Respiratory Medicine, 
2013. 107(8): p. 1172-1177. 
33. Ara, R. and A. Wailoo. The use of health state utility values in decision models. 2012; 
Available from: http://scharr.dept.shef.ac.uk/nicedsu/wp-
content/uploads/sites/7/2016/03/TSD12-Utilities-in-modelling-FINAL.pdf. 
34. National Institute for Health and Care Excellence. Mepolizumab for treating severe refractory 
eosinophilic asthma. Final appraisal determination. 2017; Available from: 
https://www.nice.org.uk/guidance/ta431/documents/final-appraisal-determination-document. 
 
